**Figure 5. Sensitivity of VEGF signaling is enhanced by PKA.** Serum-free culture of Flk1⁺ cells on two-dimensional condition, at Flk-d3. (A-B) Flow cytometry for CD31 expression in the presence (Dox⁺; 1 µg/mL) or absence (Dox⁻) of Dox. x-axis: CD31; y-axis: SSC. Flk1⁺ cells were incubated with various concentrations of VEGF₁₆₅ or VEGF₁₂₁ in serum-free medium, SFO3. Percentages of CD31⁺ ECs in total Flk1⁺ cell–derived cells are indicated. (B) Quantitative evaluation of effects of PKA activation on EC differentiation. Percentages of CD31⁺ EC population in total Flk1⁻ cell–derived cells are evaluated (n = 3; *P < .05, **P < .01 vs corresponding values; NS indicates not significant). (C) Quantitative evaluation of the number of induced ECs. Total cell number that appeared from 12.5 · 10⁴ of plated Flk1⁺ cells at Flk-d3 is shown.

VEGF₁₆₅ and VEGF₁₂₁ on Flk1⁺ cells using serum-free culture with a defined medium, SFO3 (including insulin, transferrin, sodium selenite, and ethanolamine).[25] In the serum-free condition, CD31⁻ ECs were not induced from Flk1⁺ progenitors in the absence of VEGF₁₆₅. In the control condition (Dox⁻), 5 to 50 ng/mL VEGF₁₆₅ induced CD31⁺ ECs. Surprisingly, although almost no ECs were induced in the absence of VEGF₁₆₅ even with CA-PKA activation (Dox⁻), CA-PKA expression induced distinct EC appearance in much lower concentration of VEGF₁₆₅ (ie, 0.5-5 ng/mL; Figure 5A-B). Similar or higher amounts of ECs were induced by 10 times lower concentration of VEGF₁₆₅ in Dox⁻ condition compared with those in Dox⁻ condition (CD31⁻ cells: 18.1% ± 5.1% [Dox⁻, 0.5 ng/mL VEGF₁₆₅] vs 14.2% ± 4.8% [Dox⁺, 5 ng/mL VEGF₁₆₅]; 34.6% ± 2.4% [Dox⁻, 5 ng/mL VEGF₁₆₅] vs 25.2% ± 4.8% [Dox⁺, 50 ng/mL VEGF₁₆₅]; Figure 5B). There was no difference observed in the total cell number that appeared from Flk1 cells between Dox⁺ and Dox⁻ treatment (Figure 5C), suggesting that PKA activation should enhance EC differentiation but not proliferation. Furthermore, the potent enhancement of EC differentiation was observed specifically by VEGF₁₆₅ treatment, and not by VEGF₁₂₁, which does not bind to NRP1 (Figure 5A).[26] Significant increase in EC appearance with 50 ng/mL VEGF₁₂₁ (Figure 5B) should

be induced by binding of VEGF₁₂₁ to up-regulated Flk1. Similarly, addition of 8bromo-cAMP in Dox⁻ condition also enhanced response of Flk1⁺ progenitor differentiation to VEGF (supplemental Figure 9). These results indicate that dual activation of Flk1 and NRP1 by PKA activation markedly enhanced sensitivity of Flk1⁻ progenitors to VEGF₁₆₅.

PKA activation induces Flk1-VEGF-NRP1 complex formation

Finally, we confirmed the formation and function of Flk1-VEGF₁₆₅-NRP1 complex by PKA activation. One day after Flk1⁺ cell culture in serum-free conditions (Flk-d1), cells were collected and protein interaction of Flk1, NRP1, and VEGF was examined by immunoprecipitation assay.[31] Western blot analysis for NRP1 using total cell lysates clearly revealed increase in NRP1 protein by CA-PKA expression (Dox⁻) at Flk-d1 (Figure 6Aii). Total NRP1 expression was increased approximately 4.3-fold by PKA activation (n = 6; P < .001). In various conditions that we tested, only when added together with CA-PKA expression (Dox⁻), VEGF₁₆₅ formed a distinct protein complex with Flk1 and NRP1 (Figure 6Ai lane 7). The protein complex was not formed in the control conditions (Dox⁺) or Dox⁻ conditions with the addition of VEGF₁₂₁. Similarly,

A

B

C

Figure 6. PKA enhanced to form Flk1-VEGF-NRP1 complexes. (A) Immunoprecipitation assay. Formation of Flk1-VEGF-NRP1 complex was examined at Flk-d1 cultured with serum-free medium, SFO3. Immunoblot with anti-NRP1 antibody for cell lysates immunoprecipitated with anti-Flk1 antibody (Ai) and total cell lysates (Aii). (Ai) Note that a distinct band was observed only when $VEGF_{165}$ was added to PKA-activated (Dox$^-$) condition (lane 7), which was inhibited by addition of anti-VEGF or anti-NRP1 antibodies. (Aii) Total NRP1 expression was markedly increased in PKA-activated condition. (B) Two-dimensional culture of Flk1$^+$ cells with DM, at Flk-d3. Fluorescent staining for CD31 (green). Nuclei are stained with DAPI (blue). (Top left panel) Dox treatment. (Other panels) Dox-free. (Bottom left panel) Dox-free with neutralizing antibody for VEGF. (Bottom right panel) Dox-free with neutralizing antibody for NRP1. Scale bars represent 250 μm. (C) Vascular formation from Flk1$^+$ cell aggregates in three-dimensional culture. (Top left panel) Dox treatment. (Other panels) Dox-free. (Bottom left panel) Dox-free with neutralizing antibody for VEGF. (Bottom right panel) Dox-free with neutralizing antibody for NRP1. Scale bars represent 100 μm.

8bromo-cAMP treatment also induced formation of a protein complex with Flk1, NRP1, and $VEGF_{165}$ (supplemental Figure 7B). These results clearly indicated that PKA activation induced both Flk1 and NRP1 expression in vascular progenitors, and $VEGF_{165}$ in turn specifically induced the protein complex formation of Flk1-$VEGF_{165}$-NRP1. The formation of Flk1-$VEGF_{165}$-NRP1 complex was completely blocked by the addition of anti-VEGF or anti-NRP1 neutralizing antibodies (Figure 6Ai lanes 8-9). Parallel to the Flk1-$VEGF_{165}$-NRP1 complex formation, the CA-PKA–induced EC differentiation as well as vascular formation in three-dimensional culture were drastically inhibited by the addition of anti-VEGF or NRP1 neutralizing antibodies, suggesting a functional significance of the Flk1-$VEGF_{165}$-NRP1 complex (Figure 6B-C). These results indicate that PKA regulates sensitivity of vascular progenitors to VEGF by dual induction of Flk1 and NRP1, which forms the Flk1-$VEGF_{165}$-NRP1 complex enhancing VEGF signaling to efficiently induce EC differentiation and vascular formation.

Discussion

Here, we showed a novel regulatory mechanism of EC differentiation and vascular formation through the modulation of progenitor properties to be endothelial competent. PKA activation increased both Flk1 and NRP1 expression in vascular progenitors and markedly enhanced the "sensitivity" of the progenitors to $VEGF_{165}$ by inducing Flk1-$VEGF_{165}$-NRP1 complex formation. This new-mode regulatory system would provide insights in vascular development and offer options for various therapeutic strategies with vascular manipulation.

Vascular formation is regulated by appropriate intensity, space, and timing of VEGF signaling. This study showed that PKA is involved in vascular formation process through its novel function regulating VEGF signal intensity. Various factors, such as adrenomedullin,[38] prostaglandins,[39] adiponectin,[40] ghrelin,[41] klotho,[42] and mechanical stress, especially fluid shear stress,[43] have been reported to activate PKA in ECs. We previously demonstrated that adrenomedullin could enhance EC differentiation from Flk1$^+$ cells through cAMP signaling.[26] Fluid shear stress was reported to enhance EC differentiation from Flk1$^+$ cells by up-regulating VEGF receptors,[44] and to induce Flk1 gene expression in EC cell lines.[45] These multiple PKA-activating signals should be involved in vascular development to modulate the progenitor sensitivity in vivo.

We previously reported that adrenomedullin/cAMP pathway induced differentiation of arterial ECs.[26] We also examined involvement of PKA in arterial-venous specification. Whereas addition of PKI, PKA inhibitor, to Flk1$^+$ cell culture with VEGF and 8bromo-cAMP significantly decreased total CD31$^+$ EC appearance (Figure 2A-D), PKI did not inhibit ephrinB2- or CXCR4-positive arterial EC differentiation (supplemental Figure 10). Moreover, expression of CA-PKA with VEGF did not induce arterial ECs from Flk1$^+$ vascular progenitors (supplemental Figure 11). These results indicated that PKA is not involved in arterial-venous specification. Activation of PKA in Flk1$^+$ cells did not induce prox1- or podoplanin-positive lymphatic ECs (supplemental Figure 11), further suggesting that PKA pathway is involved in common EC differentiation but not in EC specification processes.

Some studies have reported the roles of downstream molecules of Flk1 signaling in EC proliferation and differentiation. Tyrosine residue 1173 of Flk1 (Y1173, corresponding to Y1175 in human Flk1, KDR) is essential for Flk1 function in vasculogenesis.[46] Y1175 of KDR is a binding site of PLCγ and is important for VEGF-dependent EC proliferation.[47] Furthermore, Ras signaling acting downstream of Flk1 signaling plays a critical role in EC differentiation.[32] Indeed, PLC inhibitor, U73122, or H-Ras inhibitor, FTI-277, showed an inhibitory effect on EC differentiation from Flk1$^+$ cells (supplemental Figure 12), indicating that PLC and Ras pathway are both downstream molecules of Flk1 signaling. Enhanced VEGF signaling in vascular progenitors by PKA should be mediated by these molecules to induce basal EC differentiation.

Molecular mechanisms of PKA to induce and/or maintain Flk1 and NRP1 expression in vascular progenitors are largely unknown. NRP1 expression was reported to be up-regulated by cAMP/PKA pathway in olfactory neuron guidance.[48] Some other reports have shown that PKA pathway enhances differentiation of neuronal progenitor cells,[49] hippocampal progenitor cells,[50] and oligodendrocyte progenitor cells.[51] Recently, evidence is accumulating to suggest that blood vessels and nerves share a similar molecular machinery to form their networks.[52] Blood vessels and nerves may use PKA as common regulatory cues for their differentiation and

development. Further elucidation of molecular interaction among PKA, Flk1, and NRP1 should provide a novel molecular framework for tissue development.

Very recently, Cimato et al reported that NRP1 was largely coexpressed with Flk1 to identify endothelial precursors in human and mouse ES cells.[53] We confirmed that low-level expression of NRP1 was observed in Flk1⁺ progenitors and was increased in ECs (supplemental Figure 13). These 2 functional markers for EC progenitors, Flk1 and NRP1, were, thus, commonly regulated by PKA to efficiently enhance their progenitor potentials responding to VEGF signaling.

We have succeeded in uncovering novel roles of PKA in EC differentiation and vascular development using our unique ES cell differentiation system. Elucidation of the new-mode cell fate determination mechanisms by modulation of progenitor potentials would provide novel insights in developmental biology, stem cell biology, and regenerative medicine.

Acknowledgments

Authorship

Correspondence: Jun K. Yamashita, Laboratory of Stem Cell Differentiation, Stem Cell Research Center, Institute for Frontier Medical Sciences, Kyoto University, 53 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507 Japan; e-mail: juny@frontier. kyoto-u.ac.jp.

References

1. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438(7070):937-945.

2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.

3. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.

4. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39(5):469-478.

5. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277(5322):48-50.

6. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 1995;10(1):135-147.

7. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269(43):26988-26995.

8. Millauer B, Wizigmann-Voos S, Schnürch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993; 72(6):835-846.

9. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376(6535): 62-66.

10. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376(6535):66-70.

11. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development. 1999;126(13):3015-3025.

12. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A. 1998;95(16): 9349-9354.

13. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996; 380(6573):435-439.

14. Miquerol L, Langille BL, Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development. 2000;127(18):3941-3946.

15. Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development. 1995;121(12):4309-4318.

16. Kawakami A, Kitsukawa T, Takagi S, Fujisawa H. Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system. J Neurobiol. 1996;29(1):1-17.

17. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell. 1997;90(4):739-751.

18. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell. 1997;90(4):753-762.

19. Geretti E, Shimizu A, Klagsbrun M. Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis. 2008; 11(1):31-39.

20. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92(6):735-745.

21. Yamaguchi TP, Dumont DJ, Conlon RA, Breitman ML, Rossant J. flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development. 1993;118(2):489-498.

22. Eichmann A, Corbel C, Nataf V, Vaigot P, Bréant C, Le Douarin NM. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci U S A. 1997;94(10):5141-5146.

23. Kennedy M, Firpo M, Choi K, et al. A common

precursor for primitive erythropoiesis and definitive haematopoiesis. Nature. 1997;386(6624): 488-493.

24. Nishikawa SI, Nishikawa S, Hirashima M, Matsuyoshi N, Kodama H. Progressive lineage analysis by cell sorting and culture identifies FLK1-VE-cadherin⁺ cells at a diverging point of endothelial and hemopoietic lineages. Development. 1998;125(9):1747-1757.

25. Yamashita J, Itoh H, Hirashima M, et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000; 408(6808):92-96.

26. Yurugi-Kobayashi T, Itoh H, Schroeder T, et al. Adrenomedullin/cyclic AMP pathway induces Notch activation and differentiation of arterial endothelial cells from vascular progenitors. Arterioscler Thromb Vasc Biol. 2006;26(9):1977-1984.

27. Era T, Witte ON. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A. 2000;97(4):1737-1742.

28. Zambrowicz BP, Imamoto A, Fiering S, Herzenberg LA, Kerr WG, Soriano P. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci U S A. 1997; 94(8):3789-3794.

29. Orellana SA, McKnight GS. Mutations in the catalytic subunit of cAMP-dependent protein kinase result in unregulated biological activity. Proc Natl Acad Sci U S A. 1992;89(10):4726-4730.

30. Toda Y, Kono K, Abiru H, et al. Application of tyramide signal amplification system to immunohistochemistry: a potent method to localize antigens that are not detectable by ordinary method. Pathol Int. 1999;49(5):479-483.

31. Pan Q, Chathery Y, Wu Y, et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem. 2007; 282(33):24049-24056.

32. Kawasaki K, Watabe T, Sase H, et al. Ras signaling directs endothelial specification of VEGFR2⁺ vascular progenitor cells. J Cell Biol. 2008;181(1):131-141.

33. Hogan B, Beddington R, Constantini F, Lacy E. *Manipulating the Mouse Embryo: A Laboratory Manual.* Cold Spring, New York: Cold Spring Harbor Laboratory Press; 1994.

34. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. *Cancer Chemother Pharmacol.* 1995;36(5):418-424.

35. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. *Cell.* 1998;93(5):741-753.

36. Adams RH, Wilkinson GA, Weiss C, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. *Genes Dev.* 1999;13(3):295-306.

37. You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ, Tsai SY. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. *Nature.* 2005;435(7038):98-104.

38. Miyashita K, Itoh H, Sawada N, et al. Adrenomedullin promotes proliferation and migration of cultured endothelial cells. *Hypertens Res.* 2003;26:S93-S98.

39. Birukova AA, Zagranichnaya T, Fu P, et al. Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. *Exp Cell Res.* 2007;313(11):2504-2520.

40. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. *Circulation.* 2000;102(11):1296-1301.

41. Rossi F, Bertone C, Petricca S, Santiemma V, Ghrelin inhibits angiotensin II-induced migration of human aortic endothelial cells. *Atherosclerosis.* 2007;192(2):291-297.

42. Yang J, Matsukawa N, Rakugi H, et al. Upregulation of cAMP is a new functional signal pathway of Klotho in endothelial cells. *Biochem Biophys Res Commun.* 2003;301(2):424-429.

43. Csiszar A, Labinskyy N, Smith KE, et al. Down-regulation of bone morphogenetic protein 4 expression in coronary arterial endothelial cells: role of shear stress and the cAMP/protein kinase A pathway. *Arterioscler Thromb Vasc Biol.* 2007;27(4):776-782.

44. Yamamoto K, Sokabe T, Watabe T, et al. Fluid shear stress induces differentiation of Flk-1-positive embryonic stem cells into vascular endothelial cells in vitro. *Am J Physiol Heart Circ Physiol.* 2005;288(4):H1915-H1924.

45. Urbich C, Stein M, Reisinger K, Kaufmann R, Dimmeler S, Gille J. Fluid shear stress-induced transcriptional activation of the vascular endothelial growth factor receptor-2 gene requires Sp1-dependent DNA binding. *FEBS Lett.* 2003;535(1-3):87-93.

46. Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. *Proc Natl Acad Sci U S A.* 2005;102(4):1076-81.

47. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. *EMBO J.* 2001;20(11):2768-2778.

48. Imai T, Suzuki M, Sakano H. Odorant receptor-derived cAMP signals direct axonal targeting. *Science.* 2006;314(5799):657-661.

49. Vogt Weisenhorn DM, Roback LJ, Kwon JH, Wainer BH. Coupling of cAMP/PKA and MAPK signaling in neuronal cells is dependent on developmental stage. *Exp Neurol.* 2001;169(1):44-55.

50. Kim G, Choe Y, Park J, Cho S, Kim K. Activation of protein kinase A induces neuronal differentiation of HiB5 hippocampal progenitor cells. *Brain Res Mol Brain Res.* 2002;109(1-2):134-145.

51. Shiga H, Asou H, Ito E. Advancement of differentiation of oligodendrocyte progenitor cells by a cascade including protein kinase A and cyclic AMP-response element binding protein. *Neurosci Res.* 2005;53(4):436-441.

52. Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. *Nature.* 2005;436(7048):193-200.

53. Cimato T, Beers J, Ding S, et al. Neuropilin-1 identifies endothelial precursors in human and murine embryonic stem cells before CD34 expression. *Circulation.* 2009;119(16):2170-2178.

VEGFR2-PLCγ1 axis is essential for endothelial specification of VEGFR2⁺ vascular progenitor cells

Hitoshi Sase, Tetsuro Watabe, Kyoko Kawasaki, Kohei Miyazono and Keiji Miyazawa*

Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan
*Author for correspondence (keiji-miyazawa@umin.ac.jp)

Summary

Vascular endothelial growth factor receptor 2 (VEGFR2) plays crucial roles in vasculogenesis, a process involving cell proliferation, migration and differentiation. However, the molecular mechanism by which VEGFR2 signaling directs vascular endothelial differentiation of VEGFR2⁺ mesodermal progenitors is not well understood. In this study, we examined the signal transduction pathway downstream of VEGFR2 for endothelial differentiation using an in vitro differentiation system of mouse embryonic stem-cell-derived VEGFR2⁺ cells. Using chimeric receptors composed of VEGFR2 and VEGFR3, the third member of the VEGFR family, we found that signaling through tyrosine 1175 (Y1175, corresponding to mouse Y1173) of VEGFR2 is crucial for two processes of endothelial differentiation: endothelial specification of VEGFR2⁺ progenitors, and subsequent survival of endothelial cells (ECs). Furthermore, we found that phospholipase Cγ1 (PLCγ1), which interacts with VEGFR2 through phosphorylated Y1175, is an inducer of endothelial specification. In contrast to VEGFR2, VEGFR3 does not transmit a signal for endothelial differentiation of VEGFR2⁺ cells. We found that VEGFR3 does not activate PLCγ1, although VEGFR3 has the ability to support endothelial cell survival. Taken together, these findings indicate that VEGFR2-PLCγ1 signal relay gives rise to the unique function of VEGFR2, thus enabling endothelial differentiation from vascular progenitors.

Introduction

Blood vessel formation is one of the initial events of organogenesis. Vascular progenitor cells emerge in the posterior primitive streak as vascular endothelial growth factor receptor 2 (VEGFR2)-positive mesodermal cells, and migrate into the extra-embryonic yolk sac in response to vascular endothelial growth factor (VEGF)-A (Huber et al., 2004; Hiratsuka et al., 2005). These mesodermal precursor cells, the hemangioblasts, form a cell mass referred to as the blood islands, followed by in situ differentiation into endothelial cells (ECs) and hematopoietic cells (HCs). Outer cells lining the blood islands differentiate into ECs to generate the primitive vascular plexus (vasculogenesis), whereas inner cells develop into HCs (Choi et al., 1998). Following vasculogenesis, remodeling of the vasculature (angiogenesis) occurs. New capillaries are formed from pre-existing vessels through proliferation and migration of ECs and subsequently undergo maturation, accompanied by recruitment of mural cells (MCs) such as vascular smooth muscle cells and pericytes (Yancopoulos et al., 2000; Coultas et al., 2005).

VEGFR2 plays crucial roles in vasculogenesis and hematopoiesis, as indicated by the results of analysis of VEGFR2-null mice (Shalaby et al., 1995; Shalaby et al., 1997). These mice die between embryonic days (E) 8.5 and 9.5 due to lack of organized blood vessels and reduced HCs, because of the absence of blood islands. Tyrosine-1173 (Y1173) of mouse VEGFR2 is known to play an essential role in blood vessel formation in vivo. Sakurai et al. reported that VEGFR2 Y1173F knock-in mice died between E8.5 and E9.5 because VEGFR2⁺ cells failed to migrate and form blood islands. These phenotypes are very similar to those of VEGFR2-null mice (Sakurai et al., 2005). Although these in vivo findings

indicate the importance of VEGFR2 Y1173 in the formation of blood islands, the developmental events following the formation of blood islands, including endothelial specification, have not yet been fully elucidated.

For study of signal transduction in lineage specification, it is advantageous to use differentiating embryonic stem cells (ESCs) because migration of progenitor cells to the correct microenvironment is not required. An in vitro system for analysis of ligand-dependent endothelial differentiation has been established, using mouse VEGFR2⁺ vascular progenitor cells derived from ESC (Hirashima et al., 1999; Yamashita et al., 2000; Ema et al., 2003; Watabe et al., 2003). In this system, ESC-derived VEGFR2⁺ cells differentiate into platelet-endothelial cell adhesion molecule-1-positive (PECAM1⁺) ECs upon stimulation with VEGF-A, or α smooth muscle actin-positive (αSMA⁺) MCs in the presence of serum or platelet-derived growth factor-BB. Endothelial differentiation of ESC-derived VEGFR2⁺ cells offers a model for endothelial developmental events in the outer cells that line blood islands (Yamashita et al., 2000). VEGFR2 appears to transmit a specific signal for endothelial differentiation of vascular progenitor cells, because signaling from either VEGFR1 or VEGFR3 fails to induce endothelial differentiation (Yamashita et al., 2000; Suzuki et al., 2005). However, the VEGFR2 signaling pathways directing endothelial specification remain largely unknown, although we recently demonstrated the involvement of Ras signaling in these pathways (Kawasaki et al., 2008).

In this study, we employed an expression system of chimeric receptors in mouse ESC-derived VEGFR2⁺ vascular progenitor cells to examine the VEGFR2 signaling involved in endothelial

differentiation of VEGFR2⁻ progenitor cells. We found that human VEGFR2 Y1175 is essential for induction of endothelial differentiation of VEGFR2⁺ cells, through specification of VEGFR2⁻ cells into ECs as well as subsequent survival of ECs. We also demonstrated that PLCγ1, which binds to phosphorylated Y1175 (Y1175-P) of VEGFR2, is an inducer of endothelial specification.

Results

Construction of a VEGFR3-VEGFR2 chimeric receptor

We previously found that ESC-derived VEGFR2⁺ cells differentiate into endothelial cells upon signaling from VEGFR2 but not upon signaling from VEGFR3 (Suzuki et al., 2005). Further, VEGF-C(C152S), a selective ligand for VEGFR3 (Joukov et al., 1998), failed to induce endothelial differentiation of ESC-derived VEGFR2⁺ cells (Suzuki et al., 2005). We therefore constructed a chimeric receptor (denoted R32) containing the extracellular domain of VEGFR3 fused with the transmembrane and intracellular domains of VEGFR2 (Fig. 1). Our aim was to examine the intracellular events downstream of VEGFR2 for endothelial differentiation through analysis of ESC-derived VEGFR2⁻ cells expressing the chimeric receptor.

We first examined phosphorylation of R32 by immunoblotting using anti-VEGFR2 Y1054-P antibody (Fig. 2A). Y1054 is one of the major sites of the phosphorylation required for maximal kinase activity of VEGFR2 (Dougher and Terman, 1999). We confirmed phosphorylation of the amino acid residue in R32 corresponding to Y1054 in VEGFR2, indicating that R32 is kinase-active (Fig. 2A).

We next used a luciferase reporter assay to examine whether R32 transmits signals downstream. Elk1 is a transcriptional factor that is activated by extracellular signal-regulated kinase (ERK) (also known as mitogen-activated protein kinase; MAP kinase). Activation of Elk1 was monitored by luciferase activity under control of the promoter containing the 5X GAL4 binding site, which is activated by the GAL4 DNA-binding-domain-Elk-1 fusion protein. To stimulate the chimeric receptor, we used a supernatant of HEK 293T cells transfected with a VEGF-C(C152S) expression vector. Supernatants of HEK 293T cells transfected with empty vector or a VEGF-C(C152S) expression vector were denoted sMock and sVEGF-C(C152S), respectively. Luciferase activity was upregulated in cells expressing R32 or wild-type (wt) VEGFR3 upon treatment with sVEGF-C(C152S), but not sMock, indicating that R32 and VEGFR3 activated Elk1 upon ligand stimulation (Fig. 2B). Luciferase activity was

increased in wt VEGFR2-expressing cells by treatment with recombinant VEGF-A but not with sVEGF-C(C152S) (Fig. 2B). sVEGF-C(C152S) thus selectively activated VEGFR3. Importantly, R32, when stimulated with sVEGF-C(C152S), induced luciferase activity to a degree comparable with that induced by VEGFR2 stimulated with VEGF-A (Fig. 2B).

Intracellular domain of VEGFR2 is sufficient to direct endothelial differentiation of VEGFR2⁺ vascular progenitor cells

Because the signaling activity of R32 was confirmed, we next established MGZRTcH ES stable cell lines carrying tetracycline (Tc)-regulatable R32, VEGFR3 or empty vector (denoted Tc-R32, Tc-VEGFR3, and Tc-empty, respectively). In MGZRTcH cells, a gene of interest can be introduced into the ROSA26 locus by means of the Cre-loxP system, and expression of the gene can be silenced by treatment with Tc (Masui et al., 2005).

ES cell lines were cultured for 4.5 days with Tc (1 μg/ml) for in vitro differentiation. VEGFR2⁺ cells were then sorted from these cells, and cultured in SFO3 (a serum-free basal medium originally developed for culture of hematopoietic stem cells) with VEGF-A, sMock or sVEGF-C(C152S) in the absence of Tc (transgene-expressing condition). VEGFR2⁺ cells derived from Tc-empty, Tc-R32 and Tc-VEGFR3 differentiated into PECAM1⁺ cells in response to VEGF-A, indicating that these cells retain competence for VEGF-A-dependent differentiation into ECs (Fig. 2C). VEGFR2⁺ cells derived from Tc-empty, Tc-R32 and Tc-VEGFR3 differentiated into αSMA⁺ cells upon treatment with sMock, whereas those derived from Tc-R32, but not Tc-empty or Tc-VEGFR3, differentiated into PECAM1⁻ cells upon stimulation with sVEGF-C(C152S) (Fig. 2C). The appearance of PECAM1⁺ cells was inhibited by the co-presence of VEGFR3-Fc chimera protein, confirming the effect of VEGF-C(C152S) (Fig. 2D). These PECAM1⁺ cells were also positive for other endothelial markers, including VE-cadherin, CD34 and endoglin (supplementary material Fig. S1). We therefore concluded that these PECAM1⁺ cells represent ECs. Comparable levels of expression of R32 and VEGFR3 in differentiated states were confirmed by immunostaining using an antibody that recognizes the extracellular domain of VEGFR3 (data not shown). Therefore, the differences in phenotypes between VEGFR2⁺ cells derived from Tc-R32 and Tc-VEGFR3 can be attributed to intrinsic properties of the intracellular domains of VEGFR2 and VEGFR3.

We next performed a colony formation assay to quantify the endothelial differentiation induced by R32 signaling (Fig. 2E).


VEGFR3

Xhol* Xhol**   HindIII*   Ig-like domain1-7   transmembrane region   kinase domain   NotI*
                                                  BamHI*

Xhol*   HindIII**   HindIII   BamHI   Y951 Y1054 Y1175 Y1214 NotI*
VEGFR2   Y1059 (Y1173 in mouse)

BamHI						
I	I	M	D	P	G	E
atc	atc	atg ga̲t ccc ggg gag				VEGFR3
atc	gtc	atg gat ccc gat gaa				VEGFR2
I	V	M	D	P	D	E

Fig. 1. Schematic illustration of R32 and its mutants. Restriction enzyme sites for Xhol, HindIII, BamHI and NotI were generated or destroyed without changing the amino acid residues. Asterisks and double asterisks denote generated restriction sites and destroyed sites, respectively. Mutated tyrosine residues are also shown. Y1175 in human VEGFR2 corresponds to Y1173 in mouse VEGFR2. The nucleotide sequences as well as amino acid sequence around the BamHI sites of VEGFR2 and VEGFR3 are shown in the box. The mutated base in VEGFR3 is underlined. The intracellular domain of VEGFR3 was swapped for that of VEGFR2 at the BamHI sites of VEGFR2 and VEGFR3. The transmembrane region is shaded dark gray.

A

IB : VEGFR2
Y1054-P

IB : VEGFR3
(extracellular)

IB : tubulin

B

C

D

E

Tc-empty

Tc-R32

Tc-VEGFR3

Fig. 2. Induction of endothelial cells from VEGFR2⁺ cells by R32 signaling. (A) Phosphorylation of the R32 chimeric receptor. HEK 293T cells were transfected with the indicated plasmids and subjected to immunoblotting using anti-VEGFR2 Y1054-P antibody (top panel). The lower two panels show the expression of each protein as indicated. (B) Luciferase reporter assay to detect activation of Elk1 by VEGF receptors that were stimulated as indicated. HepG2 cells were used to achieve modest expression levels, at which ligand-independent activation of the receptors is avoided. sMock treatment did not enhance luciferase activity compared with that of non-treated cells. Flt1-Fc was not added to 'sMock + VEGF-A'. Error bars represent s.d. (C) Endothelial differentiation assay of VEGFR2⁺ cells derived from Tc-empty, Tc-R32 and Tc-VEGFR3. Cells were immunostained for PECAM1 (green), αSMA (red) and nuclei (blue). Scale bars: 100 μm. (D) Endothelial differentiation assay of VEGFR2⁺ cells derived from Tc-R32 in the absence or presence of VEGFR3-Fc (5 μg/ml). Cells were immunostained for PECAM1 (green), αSMA (red) and nuclei (blue). Scale bars: 100 μm. (E) Colony formation assay of VEGFR2⁺ cells derived from Tc-empty, Tc-R32 or Tc-VEGFR3. The numbers of colonies of ECs, MCs or mixture of both were quantified. Representative data from two independent experiments are shown.

When treated with sMock, more than 95% of VEGFR2⁺ cells derived from Tc-empty, Tc-R32 and Tc-VEGFR3 formed MC colonies. When treated with sVEGF-C(C152S), about 45% of VEGFR2⁺ cells derived from Tc-R32 differentiated to form EC colonies. By contrast, EC colonies were only minimally induced from VEGFR2⁺ cells derived from Tc-empty and Tc-VEGFR3. These findings indicate that the intracellular domain of VEGFR2 is sufficient to direct endothelial differentiation of ESC-derived VEGFR2⁺ cells.

Construction of R32 mutants in which phosphorylated tyrosine residues were mutated to phenylalanine

To identify which tyrosine residue(s) in VEGFR2 are crucial for the induction of endothelial differentiation, five R32 mutants (R32Y951F, R32Y1054F/Y1059F, R32Y1175F, R32Y1214F and R32Y951F/Y1214F), in which tyrosine residues were mutated to phenylalanine, were constructed. Y951, Y1175 and Y1214 are major sites of phosphorylation of VEGFR2 (Matsumoto et al., 2005). Y951 and Y1175 are unique tyrosine residues in VEGFR2, whereas Y1214 is conserved in VEGFR2 and VEGFR3. Autophosphorylation of these mutants was confirmed, except for Y1054F/Y1059F, which was used as a negative control (Fig. 3A). We next examined signal transduction of these mutants by monitoring activation of Elk1 (Fig. 3B). R32Y951F, R32Y1214F and R32Y951F/Y1214F transactivated Elk1 reporter activities after stimulation with sVEGF-C(C152S), whereas R32Y1175F did not. This was consistent with the previous report that signaling from Y1175 leads to activation of ERK (Takahashi et al., 2001). However, because autophosphorylation of R32Y1175F was detected (Fig. 3A), we regarded R32Y1175F as a kinase-active receptor and proceeded with subsequent experiments.

Signaling through Y1175 is indispensable for endothelial differentiation of VEGFR2⁺ vascular progenitor cells

We next established stable ES cell lines carrying a Tc-regulatable R32Y951F, R32Y1175F or R32Y1214F (Tc-Y951F, Tc-Y1175F and Tc-Y1214F). VEGFR2⁺ cells derived from these cell lines were sorted and cultured in SFO3 with VEGF-A, sMock, or sVEGF-C(C152S). These cells also exhibited competence for endothelial differentiation in response to VEGF-A (Fig. 3C). Upon stimulation with sVEGF-C(C152S), VEGFR2⁺ cells derived from Tc-Y951F and Tc-Y1214F differentiated into ECs, whereas those from Y1175F failed to do so (Fig. 3C). To exclude the possibility that signals from Y951 and Y1214 compensate for each other in endothelial differentiation, we also established a stable cell line carrying Tc-regulatable R32Y951F/Y1214F (Tc-Y951F/Y1214F). VEGFR2⁺ cells derived from this cell line did not lose the ability to differentiate into ECs upon stimulation with sVEGF-C(C152S) (Fig. 3C). Comparable levels of expression of these chimeric receptors were confirmed by immunostaining in differentiated states (data not shown). These findings indicate that signals from Y951 and Y1214 are not required for endothelial differentiation but that signaling from Y1175 are required for it. We performed a colony formation assay using these cells (Fig. 3D). When treated with sMock, more than 98% of VEGFR2⁺ cells derived from the four mutant cell lines formed MC colonies. However, when treated with sVEGF-C(C152S), 25-55% of VEGFR2⁺ cells derived from Tc-Y951F, Tc-Y1214F or Tc-Y951F/Y1214F differentiated to form EC colonies. In contrast, EC colonies were rarely formed from VEGFR2⁺ cells derived from Tc-Y1175F, indicating that signaling through Y1175 is essential for endothelial differentiation.

A

IB : VEGFR2
Y1054-*P*

IB : VEGFR3
(extracellular)

IB : tubulin

B

- sMock
- sVEGF-C(C152S)

fold induction

empty R32 Y951F Y1054F/Y1059F Y1175F Y1214F Y951F/Y1214F

C

	VEGF-A	sMock	sVEGF-C (C152S)
Tc-Y951F			
Tc-Y1175F			
Tc-Y1214F			
Tc-951F/Y1214F			

D

Tc-Y951F

Number of colonies

sMock   sVEGF-C (C152S)

- MC
- Mix
- EC

Tc-Y1175F

Number of colonies

sMock   sVEGF-C (C152S)

- MC
- Mix
- EC

Tc-1214F

Number of colonies

sMock   sVEGF-C (C152S)

- MC
- Mix
- EC

Tc-951F/1214F

Number of colonies

sMock   sVEGF-C (C152S)

- MC
- Mix
- EC

Fig. 3. Y1175F mutation results in failure of R32 to induce endothelial differentiation of VEGFR2+ cells. (A) Phosphorylation of R32 chimeric receptor mutants. HEK 293T cells were transfected with the indicated plasmids and subjected to immunoblotting using anti-VEGFR2 Y1054-*P* antibody (top panel) and anti-VEGFR3 extracellular domain (middle panel). α-tubulin was used as a loading control (bottom panel). R32Y1054F/Y1059F was used as a negative control. (B) Luciferase reporter assay to detect activation of Elk1 by R32 mutants. Error bars represent s.d. (C) Endothelial differentiation assay of VEGFR2+ cells derived from Tc-Y951F, Tc-Y1175F, Tc-Y1214F and Tc-Y951F/Y1214F. Cells were immunostained for PECAM1 (green), αSMA (red) and nuclei (blue). Scale bars: 100 μm. (D) Colony formation assay of VEGFR2+ cells derived from Tc-R32 mutants. The numbers of colonies of ECs, MCs or mixture of both were quantified. Representative data from two independent experiments are shown.

Signaling from Y1175 plays crucial roles in the survival of ECs
Endothelial differentiation requires two processes: specification from VEGFR2+ progenitor cells into ECs, and subsequent survival/proliferation of ECs. We hypothesized that signaling from Y1175 plays roles in either or both processes. To test this hypothesis, endothelial survival assay was performed (Fig. 4).

We knocked down endogenous mouse VEGFR3 in order to exclude effects of signaling from endogenous VEGFR3, which is expressed in ESC-derived ECs (Suzuki et al., 2005). When ESC-derived ECs were cultured in the absence of sVEGF-C(C152S), cell number was markedly decreased within 12 hours (Fig. 4A-C). Cell number was restored in the case of ECs expressing R32 by stimulation with sVEGF-C(C152S) irrespective to the expression of endogenous mouse VEGFR3 (Fig. 4A). In contrast, cell number was not restored in ECs expressing R32Y1175F by stimulation with sVEGF-C(C152S) when endogenous mouse VEGFR3 was knocked down (Fig. 4B). These findings indicate that Y1175 is involved in the transmission of survival signals for ECs. We also examined the effect of VEGFR3 signaling on the survival of ECs (Fig. 4C). We observed increase in survival of ECs expressing transgenic human VEGFR3 by sVEGF-C(C152S), indicating that VEGFR3 also transmits survival signals for ECs. Survival of ESC-derived ECs

A

Tc-R32

fold change

- 0h
- sMock
- sVEGF-C(C152S)

scramble siRNA   VEGFR3 siRNA

B

Tc-R32Y1175F

fold change

- 0h
- sMock
- sVEGF-C(C152S)

n.s

scramble siRNA   VEGFR3 siRNA

C

Tc-VEGFR3

fold change

- 0h
- sMock
- sVEGF-C(C152S)

scramble siRNA   VEGFR3 siRNA

Fig. 4. Signaling through VEGFR2 Y1175 supports survival of ECs. Survival assay for ECs expressing R32 (A), R32Y1175F (B) or human VEGFR3 (C). Cells were treated with sMock or sVEGF-C(C152S). Cell numbers are shown as fold-changes relative to those at the point of medium change (0h). Values are the means ± s.d. *$P<0.05$ (Student's *t*-test); n.s., not significant. Endogenous mouse VEGFR3 was knocked down to exclude effects of endogenous signaling. Efficiency of knockdown was measured by quantitative RT-PCR as follows: ECs expressing R32, 60%; ECs expressing R32Y1175F, 40%; ECs expressing VEGFR3, 40%.

by sVEGF-C(C152S) was abrogated in the presence of LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K) (supplementary material Fig. S2), suggesting that the PI3K pathway is involved in endothelial survival by VEGFR3.

Neither R32Y1175F nor VEGFR3 is able to transmit signal sufficient for endothelial differentiation. VEGFR3, however, transmits survival signal for ECs, in contrast to R32Y1175F. The present in vitro system is thus suitable for analysis of each of the individual processes involved in endothelial differentiation.

Signaling from Y1175 plays crucial roles in endothelial specification of VEGFR2⁺ vascular progenitor cells

We next investigated the involvement of signaling from Y1175 in endothelial specification of ESC-derived VEGFR2⁺ cells. To do so, we examined differentiation of VEGFR2⁺ cells derived from Tc-Y1175F into ECs under culture conditions that support the survival of ECs. Fibroblast growth factor 2 (FGF-2) was used to support the survival of ECs. We first examined survival of ECs in the presence of FGF-2, and found that 0.5 ng/ml was sufficient to maintain the survival of ECs (data not shown). We next examined endothelial differentiation of VEGFR2⁺ cells in the presence of FGF-2 (0.5 ng/ml). The majority of VEGFR2⁺ cells derived from both Tc-R32 and Tc-Y1175F differentiated into MCs upon treatment with sMock (Fig. 5). Upon stimulation with sVEGF-C(C152S), significant endothelial differentiation was observed for Tc-R32-derived VEGFR2⁺ cells, but not for Tc-Y1175F-derived VEGFR2⁺ cells (Fig. 5). Signaling from Y1175 thus appears to direct endothelial specification of ESC-derived VEGFR2⁺ cells.

PLCγ1, which interacts with phosphorylated Y1175, is an inducer of endothelial specification

PLCγ1 has been reported to play roles in cell proliferation through interaction with Y1175-P in VEGFR2 (Takahashi et al., 2001; Takahashi and Shibuya, 1997). PLCγ1 deficiency in mice is lethal because vasculogenesis and erythrogenesis do not occur, though hemangioblasts appear to be present (Liao et al., 2002). We hypothesized that R32Y1175F fails to induce endothelial differentiation from ESC-derived VEGFR2⁺ cells because PLCγ1 is not activated. To elucidate the function of PLCγ1 in endothelial differentiation, we constructed a constitutively active form of PLCγ1, PalmPLCγ1, which has an additional sequence for myristoylation and palmitoylation in its N-terminus (Veri et al., 2001). We established a stable ES cell line carrying Tc-regulatable PalmPLCγ1 (Tc-PalmPLCγ1). These cells exhibited competence for endothelial differentiation in response to VEGF-A (Fig. 6A).

Expression of PalmPLCγ1 resulted in the appearance of PECAM1⁺ cells from ESC-derived VEGFR2⁺ cells in the presence, but not the absence, of FGF-2 (Fig. 6A). These PECAM1⁺ cells induced by PalmPLCγ1 and FGF-2 were also positive for other endothelial markers, such as VE-cadherin, CD34 and endoglin (supplementary material Fig. S3), indicating that they represent ECs. We performed a colony formation assay for quantification of endothelial differentiation induced by PalmPLCγ1 and FGF-2. In the absence of survival signals, expression of PalmPLCγ1 did not affect induction of EC colonies, whereas in the presence of such signals PalmPLCγ1 drastically induced formation of EC colonies (Fig. 6B). Stimulation with PalmPLCγ1 and FGF-2 thus reconstituted signaling for endothelial differentiation of ESC-derived VEGFR2⁺ progenitor cells. Because induction of endothelial differentiation by PalmPLCγ1 was observed only in the presence of survival signal for ECs, PalmPLCγ1 appears to direct endothelial

| FGF-2	+	+	+
sMock		+	
sVEGF-C(C152S)			+

Fig. 5. Signaling through VEGFR2 Y1175 is indispensable for endothelial specification of VEGFR2⁺ cells. Endothelial differentiation assay of VEGFR2⁺ cells derived from Tc-R32 and Tc-Y1175F in αMEM supplemented with 10% FBS in the presence FGF-2, and sMock or sVEGF-C(C152S). Cells were then fixed and immunostained for PECAM1 (green), αSMA (red) and nuclei (blue). Scale bars: 100 μm.

specification but not to promote the survival of ECs. We also performed a cell survival assay (Fig. 6C). Numbers of ECs expressing PalmPLCγ1 were decreased to levels comparable to those of control ECs in the absence of VEGF-A in culture (Fig. 6C). These findings indicate that PLCγ1 signaling is involved in endothelial specification of VEGFR2⁺ cells but not in the survival of ECs.

We next established a stable ES cell line in which expression of PLCγ1 can be knocked down by microRNA (miRNA) under the control of Tc (Tc-miRNA-PLCγ1). Expression of miRNA targeting PLCγ1 resulted in modest decrease of PLCγ1 expression (Fig. 6D, right) and decreased appearance of ECs (Fig. 6D, left), thus confirming the important role of PLCγ1 in endothelial differentiation.

We previously reported that a farnesyltransferase inhibitor, FTI-277, suppressed VEGF-A-induced endothelial specification of ESC-derived VEGFR2⁺ vascular progenitor cells (Kawasaki et al., 2008). In this study, we found that FTI-277 also suppressed the endothelial differentiation induced by PalmPLCγ1 plus FGF-2 (Fig. 6E). Because FTI-277 did not inhibit FGF-2-induced survival of ECs (data not shown), the FTI-277-sensitive process is probably located downstream of PLCγ1.

Signaling from VEGFR3 fails to induce endothelial differentiation due to lack of PLCγ1 activation

As described above, VEGFR3 signaling supports the survival of ECs (Fig. 4C) but does fail to induce endothelial differentiation (Fig. 2C). We therefore anticipated that VEGFR3 would not activate PLCγ1. We found that activation of R32 by VEGF-C induced phosphorylation of PLCγ1, whereas activation of VEGFR3 by VEGF-C did not induce phosphorylation of PLCγ1 (Fig. 6F). Collectively, these findings indicate that the differences in ability to induce endothelial differentiation between VEGFR2 and VEGFR3 can be attributed to the differences between them in activation of PLCγ1. These findings further accentuate the crucial role of PLCγ1 in endothelial specification.

Discussion

The development of blood vessels requires orchestrated behavior of cells, including proliferation, migration and differentiation. These complex dynamics are mediated through a variety of receptor-dependent signaling pathways. Of the signaling pathways that

regulate the formation and maturation of blood vessels, VEGFR2 signaling is one of the most important (Olsson et al., 2006). VEGFR2 plays essential roles in the migration of VEGFR2[+] cells from the primitive streak to the extra-embryonic yolk sac (Huber et al., 2004; Hiratsuka et al., 2005), in situ differentiation into both HCs and ECs (Choi et al., 1998), and subsequent vascular remodeling processes (Yancopoulos et al., 2000; Coultas et al., 2005). In this study, we used ESC-derived VEGFR2[+] cells to examine the molecular relay of VEGFR2 signaling that leads to

endothelial differentiation. With this experimental system, we found that, among the major sites of phosphorylation of VEGFR2, Y1175 is indispensable for endothelial differentiation, whereas Y951 and Y1214 are not. We also found that signaling from Y1175 is required in two processes of endothelial differentiation: that which specifies the endothelial fate of VEGFR2[+] cells, and that which maintains the survival of ECs. Sakurai et al. previously reported that migration of VEGFR2[+] cells from the primitive streak to the yolk sac is impaired in knock-in mice, in which Y1173 of VEGFR2 has been substituted with phenylalanine (Y1173 of mouse VEGFR2 corresponds to Y1175 of human VEGFR2) (Sakurai et al., 2005). This defect results in accumulation of these cells in the allantois and amnion, and lack of blood island formation in the yolk sac (Sakurai et al., 2005). This report and the findings of the present study indicate that VEGFR2 Y1175 is involved in the formation of blood islands through effects on the migration, subsequent endothelial specification and survival of ECs. These findings indicate that signaling from Y1175 plays diverse and important roles in VEGFR2-dependent endothelial differentiation.

The roles of the major sites of phosphorylation in VEGFR2 have been investigated in 'mature' ECs. Y951 is involved in actin stress fiber organization and migration through interaction with an adaptor molecule, TSAd (T-cell-specific adaptor) (Matsumoto et al., 2005; Wu et al., 2000; Zeng et al., 2001). TSAd-deficient mice exhibited decreased tumor growth rate due to reduced vascularization in an in vivo pathological angiogenesis model (Matsumoto et al., 2005). Y1214 is implicated in actin polymerization and reorganization through activation of Cdc42 and p38 (Lamalice et al., 2004; Lamalice et al., 2006). However, Y1212F knock-in mice are viable and fertile (Sakurai et al., 2005), consistent with our finding that Y1214 does not play a role in endothelial differentiation. Phosphorylation of Y1175 is known to result in recruitment and activation of PLCγ, followed by Ras-independent activation of ERK via protein kinase C (PKC), leading to enhancement of cell


Fig. 6. PLCγ1 is an inducer of endothelial specification. (A) Endothelial differentiation assay of VEGFR2[+] cells derived from Tc-PalmPLCγ1 in αMEM supplemented with 10% FBS in the presence (+) or absence (-) of FGF-2, VEGF-A and Tc. Cells were immunostained for PECAM1 (green), αSMA (red) and nuclei (blue). Scale bars: 100 μm. (B) Colony formation assay in αMEM supplemented with 10% FBS. Colonies of ECs, MCs and mixtures of both were quantified. The ratio of number of colonies is displayed in the graph. Representative data from three independent experiments are shown. (C) Survival assay for ECs expressing PalmPLCγ1. Cell numbers are shown as fold-changes relative to those at the point of medium change (0h). Cells were treated with VEGF-A or not treated. Values are the means ± s.d. (D) Colony formation assay of Tc-miR-PLCγ1 cells in which PLCγ1 expression was knocked down by miRNA in the absence of Tc. VEGF-A was used at 30 ng/ml. Colonies of ECs, MCs and mixtures of both were quantified. The ratio of number of colonies is displayed in the graph (left). For knockdown of PLCγ1, ESCs were cultured in the absence of Tc for the last 2 days of in vitro differentiation to induce expression of miRNA. Knockdown efficiencies in ESC-derived VEGFR2[+] cells were examined by immunoblotting (right). (E) Effect of FTI-277 on endothelial differentiation induced by PalmPLCγ1 and FGF-2. Endothelial differentiation assay in αMEM supplemented with 10% FBS was performed in the presence or absence of FGF-2, Tc and FTI-277 (3 μM), followed by immunostaining for PECAM1 (green), αSMA (red) and nuclei (blue). Scale bars: 100 μm. (F) Activation of PLCγ1 by ligand-stimulated R32 or VEGFR3. HEK 293T cells expressing R32 or VEGFR3 were starved for 14 hours and stimulated with recombinant VEGF-C (400 ng/ml) for 5 minutes, followed by immunoprecipitation and immunoblotting to detect phosphorylation of PLCγ1.

proliferation (Takahashi et al., 1999; Takahashi et al., 2001). Phosphorylation of Y1175 has also been reported to trigger activation of PI3K to promote cell survival, as well as activation of focal adhesion kinase (FAK) to regulate formation of stress fibers and focal adhesions via the adaptor protein Shb (Dayanir et al., 2001; Holmqvist et al., 2004). Y1054 and Y1059 have been found to be required for maximal kinase activity of VEGFR2 (Dougher and Terman, 1999). Although VEGFR2 signaling pathways mediating cell proliferation and migration have been well explored, those directing endothelial differentiation in vascular progenitor cells have remained largely unknown.

In this study, we have demonstrated that signaling through VEGFR2 Y1175 is involved in endothelial specification of VEGFR2+ cells and subsequent survival of ECs. We further examined the role of PLCγ1, an effector that interacts with Y1175-P, in VEGFR2-mediated endothelial differentiation. We found that PLCγ1 enhances endothelial differentiation in the presence of survival signal, suggesting that the VEGFR2-PLCγ1 axis mediates endothelial specification but not the survival of ECs (Fig. 6A-C). Importantly, our finding that PLCγ1 plays an essential role in endothelial specification is consistent with a previous report on PLCγ1-deficient mice. Liao et al. reported that vasculogenesis and erythrogenesis were not observed in PLCγ1-null mice, though non-erythroid granulocytes and macrophages were present (Liao et al., 2002). These observations suggest that hemangioblasts are present, but that the subsequent differentiation into ECs or cells of the erythroid lineage is impaired in the absence of PLCγ1. They also suggested the possibility that impaired vasculogenesis in PLCγ1-null mice might be due to failure of survival of endothelial progenitors, because PLCγ1 also plays roles in cell survival (Lee et al., 1999; Wang et al., 2001). However, the findings of our colony formation assay (Fig. 6B) and endothelial survival assay (Fig. 6C) revealed that the principal role of PLCγ1 during endothelial differentiation of VEGFR2+ progenitor cells is to direct endothelial specification and not to support cell survival. PLCγ2 is also expressed in VEGFR2+ cells and ECs, as well as PLCγ1 (data not shown). PLCγ2-deficient mice were viable, although they were obtained at approximately two-thirds the expected frequency and were often smaller than wild-type mice, presumably because of occasional hemorrhage (Wang et al., 2000). Given the difference in phenotype between PLCγ1-null mice and PLCγ2-null mice, PLCγ1 appears to play more crucial roles than PLCγ2 in the process of development of the vasculature.

We recently reported that Ras signaling plays an important role in VEGF-A-dependent endothelial specification of VEGFR2+ cells (Kawasaki et al., 2008). VEGF-A induces delayed Ras activation 6-9 hours after stimulation in VEGFR2+ vascular progenitor cells, which specifies endothelial differentiation. In this study, our findings suggested that the VEGFR2-PLCγ1 axis is upstream of Ras signaling because the endothelial specification induced by PLCγ1 signaling was abrogated by FTI-277, a farnesyltransferase inhibitor that inhibits H-Ras (Fig. 6E). It will be important to determine the link between activation of PLCγ1 and the delayed Ras activation in the transmission of signaling for endothelial specification. Activation of PLCγ results in formation of diacylglycerol and inositol-1,4,5-triphosphate [Ins(1,4,5)P_3]. The former activates the C1-domain-containing molecules including PKCs and Ras guanine-releasing proteins (RasGRPs) (Kazanietz, 2000), whereas the latter triggers Ca^{2+} signaling pathways. VEGFR2-induced PLCγ signaling activates Erk through PKC (Takahashi et al., 1999). PKC is also reported to activate Ras

(Marais et al., 1998) although the detailed mechanism still remains to be determined. These two pathways, however, do not appear to be involved in the delayed Ras activation by VEGF-A in VEGFR2+ cells, because U0126 (a MEK inhibitor) and Go6983 (a PKC inhibitor) did not affect Ras activation although they inhibited endothelial differentiation induced by VEGF-A (supplementary material Figs S4 and S5). Thus, other pathways downstream of PLCγ1 appear to induce the delayed Ras activation. Notably, we did not observe the delayed activation of Ras after VEGF-A stimulation in human microvascular endothelial cells (Kawasaki et al., 2008), suggesting that Ras might be activated through a mechanism unique to VEGFR2+ vascular progenitor cells. It is possible that the delayed Ras activation is mediated through transcriptional induction of certain signaling molecules.

Akt has been reported to play an essential role in VEGF-A-induced endothelial survival (Fujio and Walsh, 1999). By contrast, the PI3K-Akt pathway is not involved in endothelial specification (Kawasaki et al., 2008). Thus, it appears likely that the PI3K-Akt pathway contributes to endothelial differentiation through supporting cell survival. We also found that the PI3K-Akt pathway is involved in endothelial survival by VEGFR3 signaling. The PI3K-Akt pathway can be activated by Ras, but it appears to be activated independently of Ras in VEGF-A-stimulated VEGFR2+ vascular progenitor cells, because FTI-277 inhibited phosphorylation of Erk but not Akt at 6 hours after VEGF-A-stimulation (supplementary material Fig. S6).

Our findings are schematically summarized in Fig. 7. In conclusion, we found that signaling through VEGFR2 Y1175 is indispensable for endothelial specification and subsequent survival of ECs, which are two elementary processes in endothelial differentiation. We also demonstrated that signaling for endothelial specification, a function of VEGFR2 characteristic among the VEGFR family members, is mediated by VEGFR2-PLCγ1 signal relay via VEGFR2 Y1175.


Fig. 7. Hypothetical model of endothelial differentiation of VEGFR2+ cells. PLCγ1 is phosphorylated through interaction with Y1175-P of VEGFR2 in response to VEGF-A stimulation. The VEGFR2-PLCγ1 signaling axis might lead to activation of Ras, one of the pivotal regulators of endothelial specification. PI3K might also be activated via VEGFR2 Y1175-P to maintain survival of ECs. VEGFR3 does not induce endothelial specification of VEGFR2+ cells, presumably because VEGFR3 fails to activate PLCγ1, although VEGFR3 has the potential to maintain the survival of ECs via PI3K.

Materials and Methods

Construction of a chimeric receptor and its mutants

cDNAs coding for human VEGFR2 and VEGFR3 were described previously (Suzuki et al., 2005). All chimeric receptors were cloned into the pPthC vector. The chimeric receptor denoted R32 contains the extracellular domain of VEGFR3 fused with the transmembrane and the intracellular domain of VEGFR2. R32 was constructed by a PCR-based method as follows. Restriction sites were generated or destroyed with amino acid residues being unaffected, as shown in Fig. 1. A BamHI site was generated in the intracellular domain of VEGFR3 at 2451-2456 bp from the translational start site, which corresponds to the BamHI site (2418-2423 bp) in VEGFR2. The intracellular domain of VEGFR3 was swapped with that of VEGFR2 at the BamHI sites of VEGFR2 and VEGFR3. R32Y951F, R32Y1054F/1059F, R32Y1175F, R32Y1214F and R32Y951F/Y1214F, in which tyrosine residues were mutated to phenylalanine, were also generated from R32 by a PCR-based method.

Reagents and antibodies

VEGF-A (VEGF-A165), FGF-2 and Flt1-Fc were purchased from R&D Systems (Flanders, NJ). VEGF-C, FTI-277, U0126, LY294002 and Go6983 were from Calbiochem (La Jolla, CA). VEGFR3-Fc was from Sigma. The following antibodies were used: anti-VEGFR2 Y1054-P (44-1046, Invitrogen, Carlsbad, CA), anti-VEGFR3 (sc-28297, Santa Cruz Biotechnology, Santa Cruz, CA), anti-tubulin (Sigma-Aldrich), anti-PLCγl (sc-81, Santa Cruz Biotechnology), anti-phosphotyrosine (PY20, BD Pharmingen, San Diego, CA), anti-VEGFR2 (Avas12, BD Pharmingen), anti-PECAM1 (Mec13.3, BD Pharmingen), anti-αSMA (1A4, Sigma-Aldrich), anti-VE-cadherin (11D4.1, BD Pharmingen), anti-CD34 (RAM34, BD Pharmingen), anti-endoglin (MJ7/18, BD Pharmingen), anti-phospho-p44/42 (#9101S, Cell Signaling Technology), anti-phospho-Akt (#9271S, Cell Signaling Technology), anti-Erk (1B3B9, Millipore), secondary antibodies conjugated with Alexa Fluor 488, 594 or 647 anti-rat/mouse IgG (Invitrogen Molecular Probes), and anti-PE conjugated with magnetic beads (Miltenyi Biotec, Auburn, CA). TOTO3 iodide for nuclear staining was from Invitrogen Molecular Probes.

Cells and cell culture

HEK 293T and HepG2 cells, obtained from American Type Culture Collection (Manassas, VA), were cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma, St Louis, MO) supplemented with 10% fetal bovine serum (FBS). MGZRTcH ESCs were obtained from Hitoshi Niwa (RIKEN Center for Developmental Biology, Kobe, Japan). The CCE ESC line was obtained from Martin J. Evans (University of Cambridge, Cambridge, UK). Maintenance, differentiation, culture and magnetic-activated cell sorting (MACS) of ESCs were performed as described previously (Yamashita et al., 2000). Stable ES cell lines carrying Tc-regulatable R32 mutants, PalmPLCγl and miRNA targeting PLCγl were established and cultured as described previously (Kawasaki et al., 2008). The pre-miRNA sequence targeting mouse PLCγl was selected as 5'-TCAAGAAGAACTTAGGAGTCCGTTTTGGCCACT-GACTGACGGACTCCTGTTCTTCTTGA-3' and used as 16 tandem repeats (Kawasaki et al., 2008). For endothelial differentiation assay, mouse ESC-derived VEGFR2⁺ cells were plated on type IV collagen-coated eight-well CultureSlides (IWAKI, Chiba, Japan) at 2.5×10⁴ cells per well and cultured for 2 days in SFO3 (Sanko Junyaku, Tokyo, Japan), or at 1.5×10⁴ cells per well and cultured for 2-4 days in αMEM (Gibco, Grand Island, NY) supplemented with 10% FBS, in the presence or absence of VEGF-A (30 ng/ml), FGF-2 (0.5 ng/ml), sMock or sVEGF-C(C152S). For colony formation assay, ESC-derived VEGFR2⁺ cells were plated at 1.0-4.0×10³ cells per well on type IV collagen-coated one-well CultureSlides and further cultured for 2-4 days in SFO3 medium or αMEM supplemented with 10% FBS, in the presence of various ligands, reagents and supernatants. ESC-derived VEGFR2⁺ cells were cultured in SFO3 medium except as noted otherwise.

Preparation of sVEGF-C(C152S)

cDNA encoding mouse VEGF-C(C152S) was described previously (Suzuki et al., 2005). The coding region was subcloned into pcDEF vector (Goldman et al., 1996). For preparation of cell culture supernatants, HEK 293T cells were transfected with pcDNA3 or a VEGF-C(C152S) expression vector by FuGene6 (Roche Diagnostics, Indianapolis, IN). After 24 hours, cells were washed twice with serum-free medium and further cultured in DMEM containing 5 mM glutamax (Gibco) for an additional 72 hours. Supernatants of HEK 293T cells transfected with empty vector or VEGF-C(C152S) expression vector were denoted sMock and sVEGF-C(C152S), respectively. sVEGF-C(C152S) had a VEGFR3-stimulating activity that was equivalent to 1.5 μg/ml of recombinant VEGF-C, as determined by luciferase reporter assay. Flt1-Fc chimera (300 ng/ml) was added to sMock or sVEGF-C(C152S) for removal of endogenous VEGF-A produced by HEK 293T cells, but was not added to the 'sMock plus VEGF-A' used in the luciferase assay. Flt1-Fc (300 ng/ml) was sufficient for neutralizing recombinant VEGF-A up to 60 ng/ml.

Luciferase assay

Activation of Elk1 was measured by the GAL4 DNA-binding-domain (DB)-Elk1 fusion system (PathDetect in vivo signal transduction pathway trans-reporting system, Stratagene, La Jolla, CA). HepG2 cells were transfected with plasmids as follows: Renilla expression vector under control of thymidine kinase promoter,

luciferase expression vector under control of 5X GAL4 binding site, DB-Elk1 fusion protein expression vector, chimeric receptor expression vectors, and tetracycline-sensitive transactivator expression vector. At 24 hours after transfection, cells were treated with sMock, sMock plus VEGF-A (100 ng/ml) or sVEGF-C(C152S). After 6 hours, cells were harvested and luciferase assay was performed according to the manufacturer's protocol (Promega, Madison, WI).

Immunocytochemistry

Cells were fixed in 1:1 acetone-methanol solution, followed by incubation with primary antibodies and then with secondary antibodies, as described previously (Kano et al., 2005).

siRNA

Three siRNAs against mouse VEGFR3 (Flt4) were purchased from Invitrogen. Equal amounts of Flt4-MSS204362, Flt4-MSS204363 and Flt4-MSS204364 were mixed and used to knock down mouse VEGFR3.

Survival assay for ECs

Mouse ESC-derived VEGFR2⁺ cells were plated at 2.0×10⁵ to 4.0×10⁵ cells per well on type IV collagen-coated six-well plates and cultured in SFO3 to differentiate into mature ECs by stimulation with VEGF-A (30 ng/ml). To exclude effects of endogenous mouse VEGFR3 expressed in ECs, ESC-derived VEGFR2⁺ cells were reverse-transfected with negative control siRNA or VEGFR3 siRNA (5 nM) by HiPerfect (Qiagen, Chatsworth, CA). After 36-42 hours of culture of the ESC-derived VEGFR2⁺ cells in SFO3 with VEGF-A, the medium was changed to one containing sMock or sVEGF-C(C152S). Cells were counted at the point of medium exchange and 12 hours after medium exchange. RNA was also prepared to examine the efficiency of knockdown of endogenous VEGFR3 at the point of medium exchange.

RNA isolation and quantitative RT-PCR

Total RNA was prepared using RNeasy (Qiagen) and reverse-transcribed with the SuperScript III first-strand synthesis system (Invitrogen). Expression of mouse VEGFR3 was measured by quantitative RT-PCR. The primer sequences used for VEGFR3 and GAPDH were as follows: VEGFR3: 5'-TCTCCA-ACTTCTTGCGTGTCAA-3' and 5'-GCTTTGGCGCCTTCTACCAT-3'. GAPDH: 5'-TGCAGTGGCAAAGTGGAGATT-3' and 5'-TGCCGTTGAATTTGCCGT-3'. All expression data were normalized to those for GAPDH.

Ras activation assay

Determination of activated Ras was performed as described previously (Kawasaki et al., 2008).

References

Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C. and Keller, G. (1998). A common precursor for hematopoietic and endothelial cells. Development 125, 725-732.

Coultas, L., Chawengsaksophak, K. and Rossant, J. (2005). Endothelial cells and VEGF in vascular development. Nature 438, 937-945.

Dayanir, V., Meyer, R. D., Lashkari, K. and Rahimi, N. (2001). Identification of tyrosine residues in vascular endothelial growth factor receptor-2 FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J. Biol. Chem. 276, 17686-17692.

Dougher, M. and Terman, B. I. (1999). Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18, 1619-1627.

Ema, M., Faloon, P., Zhang, W. J., Hirashima, M., Reid, T., Stanford, W. L., Orkin, S., Choi, K. and Rossant, J. (2003). Combinatorial effects of Flk1 and Tal1 on vascular and hematopoietic development in the mouse. Genes Dev. 17, 380-393.

Fujio, Y. and Walsh, K. (1999). Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 274, 16349-16354.

Goldman, L. A., Cutrone, E. C., Kotenko, S. V., Krause, C. D. and Langer, J. A. (1996). Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. Biotechniques 121, 1013-1015.

Hirashima, M., Kataoka, H., Nishikawa, S., Matsuyoshi, N. and Nishikawa, S. (1999). Maturation of embryonic stem cells into endothelial cells in an in vitro models of vasculogenesis. Blood 93, 1253-1263.

Hiratsuka, S., Kataoka, Y., Nakao, K., Nakamura, K., Morikawa, S., Tanaka, S., Katsuki, M., Maru, Y. and Shibuya, M. (2005). Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos. Mol. Cell. Biol. 25, 355-363.

Holmqvist, K., Cross, M. J., Rolny, C., Hägerkvist, R., Rahimi, N., Matsumoto, T., Claesson-Welsh, L. and Welsh, M. (2004). The adaptor protein shb binds to tyrosine

1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. *J. Biol. Chem.* **279**, 22267-22275.

Huber, T. L., Kouskoff, V., Fehling, H. J., Palis, J. and Keller, G. (2004). Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. *Nature* **432**, 625-630.

Joukov, V., Kumar, V., Sorsa, T., Arighi, E., Weich, H., Saksela, O. and Alitalo, K. (1998). A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. *J. Biol. Chem.* **273**, 6599-6602.

Kano, M. R., Morishita, Y., Iwata, C., Iwasaka, S., Watabe, T., Ouchi, Y., Miyazono, K. and Miyazawa, K. (2005). VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRβ signaling. *J. Cell. Sci.* **118**, 3759-3768.

Kawasaki, K., Watabe, T., Sase, H., Hirashima, M., Koide, H., Morishita, Y., Yuki, K., Sasaoka, T., Suda, T. and Katsuki, M. et al. (2008). Ras signaling directs endothelial specification of VEGFR2 vascular progenitor cells. *J. Cell Biol.* **181**, 131-141.

Kazanietz, M. G. (2000). Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. *Mol. Carcinogen.* **28**, 5-11.

Lamalice, L., Houle, F., Jourdan, G. and Huot, J. (2004). Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. *Oncogene* **23**, 434-445.

Lamalice, L., Houle, F. and Huot, J. (2006). Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. *J. Biol. Chem.* **281**, 34009-34020.

Lee, Y. H., Kim, S., Kim, J., Young Kim, K., Kim, M. J., Ryu, S. H. and Suh, P. (1999). Overexpression of phospholipase C-γl suppresses UVC-induced apoptosis through inhibition of c-fos accumulation and c-Jun N-terminal kinase activation in PC12 cells. *Biochim. Biophys. Acta* **1440**, 235-243.

Liao, H. J., Kume, T., McKay, C., Xu, M. J., Ihle, J. N. and Carpenter, G. (2002). Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice. *J. Biol. Chem.* **277**, 9335-9341.

Marais, R., Light, Y., Mason, C., Paterson, H., Olson, M. F. and Marshall, C. J. (1998). Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. *Science* **280**, 109-112.

Masui, S., Shimosato, D., Toyooka, Y., Yagi, R., Takahashi, K. and Niwa, H. (2005). An efficient system to establish multiple embryonic stem cell lines carrying an inducible expression unit. *Nucleic Acids Res.* **33**, e43.

Matsumoto, T., Bohman, S., Dixelius, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., Wikner, C., Qi, J. H. and Wernstedt, C. et al. (2005). VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. *EMBO J.* **24**, 2342-2353.

Olsson, A. K., Dimberg, A., Kreuger, J. and Claesson-Welsh, L. (2006). VEGF receptor signalling-in control of vascular function. *Nat. Rev. Mol. Cell Biol.* **7**, 359-371.

Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. and Shibuya, M. (2005). Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. *Proc. Natl. Acad. Sci. USA* **102**, 1076-1081.

Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L. and Schuh, A. C. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature* **376**, 62-66.

Shalaby, F., Ho, J., Stanford, W. L., Fischer, K. D., Schuh, A. C., Schwartz, L., Bernstein, A. and Rossant, J. (1997). A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. *Cell* **89**, 981-990.

Suzuki, H., Watabe, T., Kato, M., Miyazawa, K. and Miyazono, K. (2005). Roles of vascular endothelial growth factor receptor 3 signaling in differentiation of mouse embryonic stem cell-derived vascular progenitor cells into endothelial cells. *Blood* **105**, 2372-2379.

Takahashi, T. and Shibuya, M. (1997). The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. *Oncogene* **14**, 2079-2089.

Takahashi, T., Ueno, H. and Shibuya, M. (1999). VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. *Oncogene* **18**, 2221-2230.

Takahashi, T., Yamaguchi, S., Chida, K. and Shibuya, M. (2001). A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. *EMBO J.* **20**, 2768-2778.

Veri, M. C., DeBell, K. E., Seminario, M. C., DiBaldassarre, A., Reischl, I., Rawat, R., Graham, L., Noviello, C., Rellahan, B. L. and Miscia, S. et al. (2001). Membrane raft-dependent regulation of phospholipase Cγ-1 activation in T lymphocytes. *Mol. Cell. Biol.* **21**, 6939-6950.

Wang, D., Feng, J., Wen, R., Marine, J. C., Sangster, M. Y., Parganas, E., Hoffmeyer, A., Jackson, C. W., Cleveland, J. L. and Murray, P. J. et al. (2000). Phospholipase Cγ2 is essential in the functions of B cell and several Fc receptors. *Immunity* **13**, 25-35.

Wang, X. T., McCullough, K. D., Wang, X. J., Carpenter, G. and Holbrook, N. J. (2001). Oxidative stress-induced phospholipase C-γl activation enhances cell survival. *J. Biol. Chem.* **276**, 28364-28371.

Watabe, T., Nishihara, A., Mishima, K., Yamashita, J., Shimizu, K., Miyazawa, K., Nishikawa, S. and Miyazono, K. (2003). TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. *J. Cell Biol.* **163**, 1303-1311.

Wu, L. W., Mayo, L. D., Dunbar, J, D., Kessler, K. M., Ozes, O. N., Warren, R. S. and Donner, D. B. (2000). VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor. *J. Biol. Chem.* **275**, 6059-6062.

Yamashita, J., Itoh, H., Hirashima, M., Ogawa, M., Nishikawa, S., Yurugi, T., Naito, M., Nakao, K. and Nishikawa, S. (2000). Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. *Nature* **408**, 92-96.

Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J. and Holash, J. (2000). Vascular-specific growth factors and blood vessel formation. *Nature* **407**, 242-248.

Zeng, H., Sanyal, S. and Mukhopadhyay, D. (2001). Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. *J. Biol. Chem.* **276**, 32714-32719.

Thyroid Transcription Factor-1 Inhibits Transforming Growth Factor-β–Mediated Epithelial-to-Mesenchymal Transition in Lung Adenocarcinoma Cells

Roy-Akira Saito,[1,2] Tetsuro Watabe,[1] Kana Horiguchi,[1] Tadashi Kohyama,[2] Masao Saitoh,[1] Takahide Nagase,[2] and Kohei Miyazono[1]

[1]Departments of Molecular Pathology and [2]Respiratory Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Abstract

Thyroid transcription factor-1 (TTF-1) is expressed in lung cancer, but its functional roles remain unexplored. TTF-1 gene amplification has been discovered in a part of lung adenocarcinomas, and its action as a lineage-specific oncogene is highlighted. Epithelial-to-mesenchymal transition (EMT) is a crucial event for cancer cells to acquire invasive and metastatic phenotypes and can be elicited by transforming growth factor-β (TGF-β). Mesenchymal-to-epithelial transition (MET) is the inverse process of EMT; however, signals that induce MET are largely unknown. Here, we report a novel functional aspect of TTF-1 that inhibits TGF-β–mediated EMT and restores epithelial phenotype in lung adenocarcinoma cells. This effect was accompanied by down-regulation of TGF-β target genes, including presumed regulators of EMT, such as Snail and Slug. Moreover, silencing of TTF-1 enhanced TGF-β–mediated EMT. Thus, TTF-1 can exert a tumor-suppressive effect with abrogation of cellular response to TGF-β and attenuated invasive capacity. We further revealed that TTF-1 down-regulates TGF-β2 production in A549 cells and that TGF-β conversely decreases endogenous TTF-1 expression, suggesting that enhancement of autocrine TGF-β signaling accelerates the decrease of TTF-1 expression and vice versa. These findings delineate potential links between TTF-1 and TGF-β signaling in lung cancer progression through regulation of EMT and MET and suggest that modulation of TTF-1 expression can be a novel therapeutic strategy for treatment of lung adenocarcinoma. [Cancer Res 2009;69(7):2783–91]

Introduction

Thyroid transcription factor-1 (TTF-1; the product of *NKX2.1* gene), a homeodomain-containing transcription factor, is a master regulator for lung morphogenesis, and TTF-1 null mice die immediately at birth, resulting from profoundly hypoplastic lungs (1). The importance of TTF-1 in human lung homeostasis is also highlighted by the findings that individuals with *TTF-1/NKX2.1* haploinsufficiency exhibit congenital pulmonary disease (2). TTF-1 is mainly expressed in type II pneumocytes and Clara cells and regulates the expression of markers of these cells, i.e., surfactant protein C (SPC) and Clara cell secretory protein (CCSP), respectively (3).

Lung cancer is the most frequent type of cancers and causes death of more than one million people annually. The prognosis remains poor despite the recent advances in chemotherapies and molecular-targeted therapies. Expression of TTF-1 has been shown in all types of lung cancers, but its frequent expression is reported in adenocacinoma (72.1%) and small cell carcinoma (90.5%; ref. 4).

Epithelial-to-mesenchymal transition (EMT) is the differentiation switch directing polarized epithelial cells into mesenchymal cells, which plays key roles during embryonic development (5, 6). Mesenchymal cells arising through EMT significantly contribute to various fibrotic conditions, and the process of tumor cell invasion is also associated with EMT. In addition to the loss of cell-cell adhesions, EMT is characterized by the up-regulation of mesenchymal markers, including fibronectin and N-cadherin, and acquisition of fibroblast-like migratory and invasive phenotypes.

Recent studies revealed that several transcription factors, including Snail, Slug, δEF-1 (ZEB1), and SIP1, are involved in the induction of EMT (7–9). These transcription factors repress expression of E-cadherin and induce EMT when overexpressed in epithelial cells. The inverse process, mesenchymal-to-epithelial transition (MET), has been shown to occur during development and to be perturbed in fibrotic disorders and cancer. In contrast to EMT, however, it is largely unknown as to which signals induce MET.

Transforming growth factor-β (TGF-β) is a multifunctional cytokine that regulates a broad range of cellular responses (10). Three isoforms of TGF-β ligands, i.e., TGF-β1, TGF-β2, and TGF-β3, show different expression profiles in various tissues, including the lung. TGF-β binds to type II and type I serine/threonine kinase receptors and transmits intracellular signals. Smads are the major transducer of TGF-β signaling; Smad2 and Smad3 are phosphorylated by the TGF-β type I receptor and form complexes with Smad4. These complexes accumulate in the nucleus and regulate transcription of target genes. TGF-β suppresses growth of epithelial cells, whereas tumor cells frequently lose the responsiveness to growth inhibitory activity of TGF-β. Moreover, TGF-β is known to promote tumor progression through a diverse repertoire of tumor cell autonomous and host-tumor interactions. TGF-β is the major mediator of EMT and is critically involved in epithelial-mesenchymal interactions during lung morphogenesis (11).

In a model of chronic renal injury, bone morphogenetic protein-7 (BMP-7) has been shown to reverse TGF-β–induced EMT (12), and this finding encouraged us to explore the therapeutic strategy to induce MET in cancer cells, most of which exist in an intermediary phenotypic state of "partial EMT" with the potential to undergo "full EMT." Here, we studied the function of TTF-1 in

lung cancer. Because TTF-1 positivity has been reported to be a good prognostic marker in patients with non–small cell lung cancer (13), we focused on lung adenocarcinoma in the present study. Our results suggest that depletion of TTF-1 in lung adenocarcinoma accelerates the process of EMT, leading to progression of cancer.

Materials and Methods

Reagents and antibodies. TGF-β1 was purchased from R&D Systems and used at the concentration of 1 ng/mL. Anti–phosphorylated Smad2, phosphorylated Smad1/Smad3, fibronectin, and Snail antibodies were from Cell Signaling. Anti–total Smad2/3, N-cadherin, E-cadherin, ZO-1, and CD31 antibodies were from BD Pharmingen (Transduction Laboratories). Anti–TTF-1 antibody was from Lab Vision Corporation. Anti–α-tubulin and pan-cytokeratin antibodies were from Sigma-Aldrich. LY364947 was from Calbiochem and used at the concentration of 3 μmol/L.

Cell lines. A549 and Lewis lung cancer (LLC) cells were from Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University. NCI-H441 (H441) cells were from American Type Culture Collection. LC-2/ad cells were from RIKEN BRC.

Cloning of the human TTF-1 cDNA. There are two alternative transcripts of *TTF-1* gene, and the short form consists of over 90% of total transcripts (14). We cloned open reading frame of the short form from the cDNAs of Lu139 cells.

Phase contrast and fluorescence microscopy. Phalloidin staining and immunocytochemical analyses were carried out, as described previously (15). Fluorescence was examined by a confocal laser scanning microscope (Carl Zeiss). Cells were also photographed using a phase-contrast microscope (Olympus).

Luciferase reporter assay. Human E-cadherin promoter construct was kindly provided by Dr. F. van Roy (Ghent University). Luciferase activity was determined as described previously (15).

Immunoblot analysis. Radioimmunoprecipitation assay buffer and lysis buffer were used for immunoblotting of TTF-1 and other proteins, respectively. Detailed procedures were described previously (16).

RNA isolation and reverse transcription–PCR. Total RNA was isolated with RNeasy (Qiagen), and first-strand cDNA was synthesized using the Superscript First-Strand Synthesis System (Invitrogen). Quantitative reverse transcription–PCR (RT-PCR) analysis was performed using the ABI PRISM 7500 Fast Real-Time PCR System (Applied Biosystems) and Power SYBR Green. The expression level was normalized to that of glyceraldehyde-3-phosphate dehydrogenase. PCR primers are listed in Supplementary Table S1.

Gelatin zymography. The cells infected with Ad-LacZ or Ad-TTF-1 were cultured with serum-free media for 48 h, and the conditioned media were collected. Equal amounts of samples were applied to a 10% (w/v) polyacrylamide gel impregnated with 1 mg/mL gelatin. After electrophoresis, the gel was stained with 0.5% Coomassie blue.

Wound healing and invasion assays. Wound healing assay was performed as described previously (16). Video time-lapse imaging was performed as described in the supplementary information. Images were analyzed using the Image J software (NIH).

Cell invasion assay was performed using a Cell Culture Insert (BD Biosciences). Collagen IC was coated on the upper side of the chamber. Cells were trypsinized and reseeded in each well at a concentration of 5×10^4 per well. After 8 h, the cells on the upper face of the filters were removed, and the cells on the lower surface were fixed in methanol and stained with 0.2% crystal violet and 20% methanol.

RNA interference and oligonucleotides. Transfection of small interfering RNA (siRNA) was performed using HiPerFect reagent (QIAGEN). Human TTF-1 siRNA (Stealth RNAi HSS144278) and negative control (Stealth RNAi 12935-200) were purchased from Invitrogen.

ELISA assay. The culture supernatantnts were acidified with 1 N HCl for 10 min, followed by neutralization with 1.2 N NaOH/0.5 mol/L HEPES. The samples were then subjected to ELISA for TGF-β2 (R&D Systems).

Animal models and statistical analyses. C57/BL6 mice, 5 to 6 wk of age, were obtained from Sankyo Laboratory. A total of 1×10^7 cells in 100 μL of PBS were injected s.c. into mice. Tumor volume was approximated by using the equation, vol $= (a \times b^2) / 2$, wherein vol is volume, a is the length of the major axis, and b is the length of the minor axis. The results were analyzed statistically by the multivariate ANOVA test using JMP6 software (SAS Institute). Survival was analyzed by Kaplan-Meier method, and P value was calculated by log-rank test. The excised samples were put into OCT compound, frozen in dry-iced acetone, and further sectioned for immunohistochemistry.

Results

Ectopic expression of TTF-1 in lung adenocarcinoma cells. A549 lung adenocarcinoma cells lack TTF-1 expression, whereas H441 cells endogenously express it (17). Adenoviral transduction of TTF-1 (Ad-TTF-1) yielded similar levels of TTF-1 transcripts in A549 cells compared with those in H441 cells infected with control adenoviruses encoding LacZ (Ad-LacZ; Supplementary Fig. S1A). TTF-1 was located in the nucleus in A549 cells infected with Ad-TTF-1 (Supplementary Fig. S1B), and the known targets of TTF-1, including CCSP and SPC, were induced 96 h after adenoviral transduction (Supplementary Fig. S1C).

TTF-1 inhibits EMT in lung adenocarcinoma cells. To study the effects of TTF-1 in lung adenocarcinoma cells, we first examined morphologic changes of A549 cells. TTF-1 caused apparent changes from an elongated shape to a polygonal or round appearance (Fig. 1A). Because formation of cell-cell adhesions is mainly dependent on E-cadherin system in epithelial cells, we further explored whether TTF-1 influences E-cadherin expression. Luciferase assay showed that TTF-1 enhances the human E-cadherin promoter activity in a dose-dependent fashion (Fig. 1B). Untreated A549 cells lacked E-cadherin expression at low cell density as confirmed by immunocytochemistry. When the cells proliferate to higher cell density, diffuse and weak E-cadherin staining was heterogeneously observed (Fig. 1C).·Forced expression of TTF-1 resulted in stronger staining of E-cadherin on the cell membrane or in the cytoplasm (Fig. 1C, *bottom left*). These findings suggested that TTF-1 might restore the epithelial property, at least partially, and prompted us to explore the effect of TTF-1 on EMT in lung adenocarcinoma cells.

Because TGF-β has been shown to elicit EMT in A549 cells (18), we further investigated the effects of TTF-1 in the presence or absence of TGF-β stimulation. In contrast to untreated A549 cells, TGF-β triggered drastic morphologic changes to a spindle-like or fibroblast-like appearance (Fig. 1C and D). E-cadherin staining was completely lost in TGF-β–treated cells, regardless of cell density, and actin reorganization was apparent by phalloidin staining, showing the induction of EMT by TGF-β. Interestingly, EMT, induced by TGF-β, was clearly inhibited by ectopic TTF-1 (Fig. 1C and D).

E-cadherin expression was enhanced by the TGF-β type I receptor inhibitor LY364947 (Supplementary Fig. S2A), suggesting that blockade of endogenous TGF-β signaling induces E-cadherin up-regulation. TTF-1 further enhanced E-cadherin expression, in addition to the effect of LY364947 (Supplementary Fig. S2A). TTF-1–mediated E-cadherin up-regulation and antagonism to TGF-β–mediated EMT were further confirmed by immunoblotting (Supplementary Fig. S2B). Besides loss of E-cadherin, EMT is characterized by up-regulation of mesenchymal markers. TGF-β–mediated up-regulation of fibronectin was antagonized by TTF-1, whereas that of N-cadherin was not significantly affected

— 333 —

Figure 1. TTF-1 inhibits TGF-β–mediated EMT. *A,* phase contrast microscopy of A549 cells infected with Ad-LacZ or Ad-TTF-1. *B,* luciferase reporter assay of human E-cadherin in A549 cells. *Bars,* SD. *C,* immunocytochemistry for E-cadherin (*green*). *Red,* TRITC-phalloidin; *blue,* TOTO3 (nuclei). A549 cells infected with Ad-LacZ or Ad-TTF-1 for 48 h were incubated with or without TGF-β1 for additional 48 h. *D,* high magnification of the cells treated as in *C. Red,* TRITC-phalloidin; *blue,* TOTO3 (nuclei).

(Supplementary Fig. S2*B*). LY364947 suppressed the induction of fibronectin and N-cadherin by TGF-β and up-regulated E-cadherin expression (Supplementary Fig. S2*B*).

In addition to E-cadherin, A549 cells were further immuno-stained for other epithelial markers, i.e., ZO-1 and pan-cytokeratin (Supplementary Fig. S3). ZO-1 expression was observed in both LacZ-expressing and TTF-1–expressing cells. In LacZ-transduced cells, TGF-β treatment led to the reduction of its staining on the cell membrane, whereas this effect was clearly antagonized by TTF-1. Pan-cytokeratin expression was decreased but sustained even after TGF-β treatment.

TTF-1 attenuates matrix metalloproteinase-2 activity, cell migration, and invasive capacity of lung adenocarcinoma cells. EMT is accompanied with enhancement of matrix metal-loproteinase (MMP) activities that facilitate degradation of extracellular matrices surrounding tumor cells. TGF-β treatment enhanced the expression of MMP-2, as determined by quantitative RT-PCR, and this effect was inhibited by TTF-1 (Fig. 2*A*). LY364947

effectively blocked the effect of TGF-β to induce MMP-2 in both of the control and TTF-1–expressing cells (Supplementary Fig. S4*A*). Gelatin zymography further showed that MMP-2 activity was enhanced by TGF-β, and this effect was inhibited by TTF-1 (Fig. 2*B*).

To analyze functional aspects of TGF-β–induced EMT and antagonistic action of TTF-1, we performed wound healing and invasion assays. TGF-β treatment led to highly migratory behavior of cells and earlier closure of wounds after 72 hours, despite of its growth inhibitory action (Fig. 2*C, top left*). Expression of TTF-1 resulted in retardation of wound closure reflecting attenuated migratory property, and TGF-β treatment failed to enhance cell migration in TTF-1–transduced cells in contrast to LacZ-trans-duced cells (Fig. 2*C, bottom left*). These effects were quantitated by time-lapse movies (Fig. 2*C, right* and Supplementary Videos).

The process of cancer invasion involves the degradation of basement membrane and extracellular matrices that are mainly composed of collagen. To determine the invasive capacity of lung

Figure 2. TTF-1 attenuates MMP-2 activity, cell migration, and invasive capacity. *A,* quantitative RT-PCR. Kinetic expression of MMP-2 after TGF-β1 treatment in LacZ-transduced or TTF-1–transduced cells. *Bars,* SD. The values indicate the fold difference compared with 0 h control of LacZ-expressing cells. *B,* gelatin zymography. Gelatin digestion by activated MMP-2 was quantified and relative intensity to control is indicated. Molecular mass markers are in kDa. *C, left,* cells infected with Ad-LacZ or Ad-TTF-1 were scratched and incubated with or without TGF-β1 for 72 h; *right,* quantitation of wound healing assay. The distance of cell migration was measured after 24 h by time-lapse video microscopy at eight fields for each group. *Bars,* SD. *D, left,* cell invasion assay. The migrated cells were stained with crystal violet. *Right,* quantitation of invasion assay. The migrated cells were counted, and the sum of five random fields was obtained for each well. Each experiment was performed in triplicate. *Bars,* SD.

cancer cells, we used chambers coated with collagen IC. TGF-β treatment resulted in increased number of migrated cells on the lower face of the chambers. TTF-1–expressing cells showed impaired migration through the filters, and the action of TGF-β was completely antagonized by TTF-1 (Fig. 2D, *left*). Quantitation of these results revealed that TTF-1 inhibited the invasive capacity of lung adenocarcinoma cells and TGF-β failed to restore it (Fig. 2D, *right*).

TTF-1 negatively regulates the expression of molecules involved in EMT. In A549 cells, ectopic TTF-1 inhibited the induction of TGF-β target genes, Smad7 and PAI-1, which are regulated by Smad pathway (Fig. 3A). Despite of these striking differences, phosphorylation of Smad2 or Smad3 after TGF-β treatment displayed no significant difference between the control and TTF-1–expressing cells (Supplementary Figs. S5A and S5B). Next, we knocked down the expression of endogenous TTF-1 in H441 cells. Transfection of TTF-1 siRNA effectively suppressed the expression of TTF-1 (Fig. 3B, *left*). TTF-1 knockdown resulted in enhanced induction of Smad7 and PAI-1 after TGF-β stimulation in H441 cells (Fig. 3B, *right*), consistent with the results in A549 cells.

Recent data have shown that Smad3 physically interacts with TTF-1 and regulates the transcription of the TTF-1 target gene SPB (19, 20). Taken together, it is suggested that TTF-1 suppresses Smad-mediated transcription of a subset of TGF-β target genes in the nucleus and, thereby, inhibits TGF-β–mediated EMT in lung adenocarcinoma cells.

We further explored the antagonistic effects of TTF-1 against TGF-β–induced EMT. Expression of E-cadherin is regulated by multiple transcription factors, including zinc finger transcriptional repressors Snail and Slug (8). TTF-1 suppressed the basal expression level of Snail and Slug, and their rapid induction after TGF-β treatment was also inhibited by TTF-1 (Fig. 3C, *left*). Suppressed expression of Snail was also shown by immunoblotting (Fig. 3C, *right*). Although LY364947 treatment suppressed the expression of Snail and Slug after 24 h in LacZ-transduced cells, it did not induce further decrease in TTF-1–transduced cells (Supplementary Figs. S4B and C).

Luciferase assay showed that Snail or Slug suppresses the human E-cadherin promoter activity, antagonizing the action of TTF-1 to enhance it (Supplementary Fig. S6A). Furthermore, adenoviral

— 335 —

transduction of human Snail resulted in down-regulation of E-cadherin and up-regulation of N-cadherin and fibronectin, mimicking the effect of TGF-β (Supplementary Fig. S6B). These results support the idea that Snail and Slug are involved in the regulation of EMT in A549 cells, as previously described in other cell types.

Recently, platelet-derived growth factor (PDGF) signaling (21) and collagen I (22) have been reported to be involved in TGF-β–induced EMT. In A549 cells, TGF-β stimulation resulted in the induction of PDGF-B and α1(I) collagen, whereas this effect was blocked by ectopic TTF-1 (Supplementary Figs. S7A and B). These results suggest that TTF-1 blocks EMT and induces epithelial differentiation by suppression of an array of events leading to EMT. In addition, induction of CTGF after TGF-β treatment was also inhibited by TTF-1 (Supplementary Fig. S7C). Thus, it is also suggested that TTF-1 can act as an antifibrotic factor in cancer, as well as in fibrotic disorders, through down-regulation of fibrotic factors.

Silencing of TTF-1 modulates epithelial phenotypes and enhances TGF-β–mediated EMT. To further address the effect of TTF-1 on TGF-β–induced EMT, we knocked down endogenous TTF-1 in H441 cells. Control or TTF-1 siRNA was transfected at 0 and 72 hours in the presence or absence of continuous TGF-β stimulation, and the cell morphology was examined at 144 hours (Fig. 4A), because it was previously reported that alveolar epithelial cells undergo EMT when chronically treated with TGF-β for >144 hours (23). Silencing of TTF-1 in H441 cells resulted in morphologic changes to a flattened or elongated shape with decreased cell-cell attachment (Fig. 4A). TGF-β treatment led to the reorganization of actin stress fibers, whereas cell-cell adhesions were sustained (Fig. 4A and Supplementary Fig. S8A). The cells with combined treatment of TTF-1 knockdown and TGF-β showed impaired cell-cell attachment, and fibroblast-like cells were frequently found when cultured at low cell density (Fig. 4A, bottom).

H441 cells were also immunostained for E-cadherin, ZO-1, and pan-cytokeratin (Supplementary Fig. S8B). E-cadherin staining on


Figure 3. TTF-1 down-regulates the molecules involved in EMT. A, quantitative RT-PCR. Kinetic expression of Smad7 and PAI-1 indicated as in Fig. 2A. B, left, immunoblotting of TTF-1 in H441 cells transfected with mock, control siRNA (si NTC), and siRNA for TTF-1 (si TTF-1). α-Tubulin was used as a loading control. Right, quantitative RT-PCR. Kinetic expression of Smad7 and PAI-1. H441 cells were transfected with si NTC or si TTF-1 and treated with TGF-β1 for the indicated time periods. C, left, quantitative RT-PCR. Kinetic expression of Snail and Slug. Right, immunoblotting of Snail in A549 cells infected with Ad-LacZ or Ad-TTF-1 and treated with or without TGF-β1 for 24 h.

— 336 —

Figure 4. Silencing of TTF-1 enhances TGF-β–mediated EMT. *A,* phase contrast microscopy of H441 cells transfected with si NTC or si TTF-1 and incubated with or without TGF-β1 for 144 h. *B,* quantitative RT-PCR. Kinetic expression of Snail and Slug indicated as in Fig. 3B. *C, left,* immunoblotting of Snail in H441 cells transfected with si NTC or si TTF-1 and treated with or without TGF-β1 for 24 h; *right,* immunoblotting of E-cadherin and mesenchymal markers (fibronectin and Snail). H441 cells were transfected with si NTC or si TTF-1 at 0 and 72 h and incubated with or without TGF-β1 for 144 h.

the cell membrane was clearly observed in H441 cells. In contrast to A549 cells, E-cadherin expression was persistent even after TGF-β treatment. TTF-1 knockdown alone failed to significantly suppress its expression, but simultaneous treatment with TGF-β resulted in loss of cell-cell adhesions and substantially decreased E-cadherin staining. Irregular staining of ZO-1 was noted in H441 cells, and TTF-1 knockdown or TGF-β treatment led to its reduced expression. Pan-cytokeratin expression was decreased but sustained even after TGF-β treatment or TTF-1 knockdown. Together with the results in A549 cells, cytokeratins might be persistently expressed in lung cancer cells with mesenchymal phenotypes, consistent with the clinical findings that most lung cancer cells keep expressing cytokeratins.

We next examined the effect of TTF-1 knockdown on both TGF-β–mediated rapid induction of Snail or Slug and expression of EMT markers. Consistent with the observations in A549 cells (Fig. 3C), silencing of TTF-1 resulted in enhanced induction of Snail and Slug (Fig. 4B). Enhanced induction of Snail was also shown by

immunoblotting (Fig. 4C, *left*). We also studied the effect of chronic exposure (144 hours) to TGF-β. TTF-1 knockdown resulted in enhanced expression of Snail, and the induction of fibronectin mediated by TGF-β was enhanced under the condition that TTF-1 was knocked down (Fig. 4C, *right*). These observations support the action of TTF-1, which inhibits EMT mediated by TGF-β. Contrary to the immunocytochemical observations (Supplementary Fig. S8B), E-cadherin expression was not significantly affected by either TGF-β treatment or TTF-1 knockdown in a bulk population of the cells cultured at high cell density (Fig. 4C, *right*). This result suggested that E-cadherin expression is retained by other mechanisms that might overcome the effect of TGF-β or TTF-1 in H441 cells cultured at high cell density.

Reciprocal regulation of TTF-1 expression and TGF-β signaling. To address the effect of TGF-β on the expression of TTF-1, we used two different lung adenocarcinoma cell lines, H441 and LC-2/ad, which endogenously express TTF-1. TGF-β treatment for 72 hours suppressed the expression of TTF-1 mRNA and protein

— 337 —

in both cell lines (Fig. 5*A* and *B*), and blockade of TGF-β signaling with LY364947 resulted in restoration of TTF-1 expression suppressed by TGF-β (Fig. 5*B*). These findings were consistent with the previous report, showing reduced expression of TTF-1 in alveolar epithelial cells undergoing EMT (23).

To examine the effect of TTF-1 on the expression of TGF-β ligands, semiquantitative RT-PCR was performed for the three isoforms of TGF-β in A549 cells. Transcription of TGF-β2 was down-regulated by TTF-1, whereas expression levels of TGF-β1 transcripts were not significantly different between the control and the TTF-1–transduced cells (Fig. 5*C*). Transcripts of TGF-β3 were not detected in A549 cells (data not shown). Down-regulation of TGF-β2 expression was further confirmed by quantitation of TGF-β2 protein in the conditioned media (Fig. 5*D*). Taken together, reciprocal regulation between TTF-1 and TGF-β signaling has been observed, suggesting that enhancement of autocrine TGF-β signaling accelerates the decrease of TTF-1 expression and vice versa.

TTF-1 inhibits tumor progression *in vivo*. To address the effect of TTF-1 *in vivo*, we used a mouse syngenic model. Mouse LLC cells stably expressing green fluorescent protein (GFP) or TTF-1 were generated by retroviral gene transfer and were inoculated into syngenic C57/BL6 mice. Retroviral transduction was confirmed by GFP fluorescence (Supplementary Fig. S9*A*). LLCs cells lacked TTF-1 expression, and ectopic TTF-1 was located in the nucleus (Supplementary Fig. S9*B*). Expression of TTF-1 resulted in retardation of tumor growth (Fig. 6*A*), and survival rate was prolonged (Fig. 6*B*). Blood vessel density was lower in the TTF-1–expressing tumor, suggesting that TTF-1 expression might affect tumor-stromal interactions (Fig. 6*C* and *D*).

Discussion

In the present study, we showed that TTF-1 inhibits EMT in response to TGF-β and restores epithelial phenotypes in lung adenocarcinoma cells, leading to suppression of cell migration and invasion. TTF-1 abrogated TGF-β–mediated induction of Snail and Slug, which regulate the changes in gene expression patterns that underlie EMT (9). On the other hand, expression profiles of other factors that have been implicated in EMT, such as δEF-1 (ZEB1) and SIP1 (15), HMGA2 (24), and Twist1 (25), suggested that they are not involved in either TGF-β–mediated EMT or the effect of TTF-1 in A549 cells (data not shown). The mechanism of how TTF-1 inhibits TGF-β–mediated EMT could be explained by multiple mechanisms. One is the suppression of Smad-mediated transcription of EMT-inducing molecules, such as Snail and Slug (Fig. 3), as suggested by the recent findings that Smad3 physically interacts with TTF-1 and regulates its transcriptional activity (19, 20). We have also shown the importance of another pathway; i.e., attenuation of autocrine TGF-β signaling by TGF-β2 down-regulation (Fig. 5).

Accumulating evidence of genomic analyses revealed that TTF-1 gene is amplified in 10% to 15% of lung adenocarcinomas, and *in vitro* studies further support the concept that TTF-1 acts as a lineage-specific oncogene (26–28). On the other hand, the functional significance of TTF-1 in other subsets of lung adenocarcinomas, wherein TTF-1 expression is reduced or lost, still remains to be elucidated.

It is reported that TTF-1 expression is high in well-differentiated carcinomas and relatively low in poorly differentiated carcinomas (13). According to the classification of lung adenocarcinomas into terminal respiratory unit (TRU) type and

Figure 5. Exogenous TGF-β down-regulates TTF-1 and TTF-1 down-regulates TGF-β2 in lung adenocarcinoma cells. *A*, quantitative PCR of TTF-1. H441 or LC-2/ad cells were treated with or without TGF-β1 for 72 h. *Bars*, SD. *B*, immunoblotting of TTF-1. H441 or LC-2/ad cells were treated with or without TGF-β1 and LY364947 for 72 h. *C*, semiquantitative RT-PCR. A549 cells infected with Ad-LacZ or Ad-TTF-1 were incubated in the presence or absence of TGF-β1 for additional 48 h. *D*, ELISA for TGF-β2. A549 cells infected with Ad-LacZ or Ad-TTF-1 were incubated in serum free media for 48 h (4 d after infection). The cells were incubated for another 48 h in the replaced serum-free media (6 d after infection). *Bars*, SD.

— 338 —